LLPA
5.5.2021 15:02:09 CEST | Business Wire | Press release
The Leading Learning Partners Association (LLPA), an international association of 32 members across 55+ countries, have successfully hosted a series of C3 cloud skills tour events in over 17 countries in a virtual setting since January 2021.
We recognize that transformation to cloud technologies requires skills transformation and most importantly, that digital transformation is about people. During this event, The LLPA in close cooperation with Microsoft and other key partners provide business leaders, executives, IT professionals, developers and Microsoft Azure consultants, an opportunity to gain valuable insights and learn from local and international leading industry experts on topics such as building high-performance teams and better ways of leveraging existing and future cloud investments. This exciting global tour is famous for bringing learning thought leaders, executives, and partners, together to collaborate and share best practices.
“Leading transformation starts with an idea, a vision and the ability to identify expectations. For this you must be informed, knowledgeable, and equipped. The sphere of cloud technology is robust and ever changing. We’re inviting IT professionals and leaders everywhere, to attend the final C3 Global Cloud Skills Tour event to gain knowledge from leading experts that will help organizations of all sizes build a future-ready workforce” says Patrick Kersten, Chairman of the Board at LLPA.
“Contrary to popular belief, digital transformation is less about technology and more about people. You can pretty much buy any technology, but your ability to adapt to an even more digital future depends on developing the next generation of skills, closing the gap between talent supply and demand, and future-proofing your own and others’ potential” – Harvard Business Review. The C3 Global Cloud Skills Tour aims to address the cloud skills gaps by ensuring all existing and future cloud customers have the technical and soft skills needed to be successful.
The LLPA will host this live 2-day event 9-10 June 2021 from 9-1pm CET joined by international speakers, Ken Taylor , President – Training Industry, Inc., Kåre Nygård , Head of Digital Consulting Norway – TietoEVRY, Mohanna Azarmandi , Chief Learning Officer – Microsoft, Jayne Groll , CEO – DevOps Institute and many others. The LLPA have more than 15 live and on-demand sessions planned, ranging from technical deep dives to digital transformation and skilling best practice sessions. We also have a great panel discussion lined up led by leading training providers from multiple regions.
“We need to adjust and embrace a more virtual way of living and more than ever it is vital that people remain closely connected. It is great to see that the global network of the Leading Learning Partner Association is showing leadership to deliver 100% virtual trainings to support our mutual customers in the continuation and acceleration of their skilling efforts to support their digital transformation strategy. These efforts have been recognized by our mutual customers and Microsoft awarded the Leading Learning Partners Association with a global Learning Partner of the year award, for their continuous commitment for accelerating cloud skills.” – Geoff Hirsch, Senior Director of Partner Channel, WW Learning & Readiness at Microsoft.
About The LLPA
Born in the Netherlands in 2013, the Leading Learning Partners Association (LLPA) is a global organization with a member presence in more than 55 countries. Our mission is to be THE global cloud skills services organization, dedicated to providing the right tools, learning resources and services at the right time to ensure cloud skills are accessible to anyone and everyone at any time across the globe.
Our extensive network of trusted members contributes to the development of expert job-ready industry professionals through hybrid learning offerings, consulting, and certification. Together, our members have trained over 500,000 students per year, covering more than 90% of the European GDP. The LLPA has been a Microsoft Partner since 2013 and awarded Microsoft Learning Partner of the Year 2020.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210505005442/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom